Lilly's Experimental Injection Results in 28% Weight Loss

Eli Lilly's newly developed experimental injection has achieved an average weight loss of 28% in clinical trial participants. This result is considered a significant advancement compared to existing obesity treatments. The injection, which has a different mechanism than Zepbound and Foundayo, contains GIP, GLP-1, and glucagon hormones, providing a triple-effect mechanism that suppresses appetite and accelerates metabolism to support weight loss. Eli Lilly states that this experimental treatment may offer a new option for managing obesity and metabolic diseases such as diabetes. The company announced that more comprehensive data on the drug's safety and efficacy profile will be shared in the coming period. Analysts highlight the potential of such triple agonists to revolutionize weight loss treatment, but note that the drug's commercial success depends on the results of larger-scale clinical trials and the regulatory approval process. This is not an investment advice.

📊 LLY — Piyasa Yorumu

▲ up · 65%

The news reveals that Lilly's weight loss treatment has demonstrated strong efficacy, which could positively impact the company's growth potential. Technical indicators also support this optimism: the RSI at 58.5 is in neutral territory but has room for upward movement, the MACD is above the signal line and positive, and the price is trading above both the 20-day and 50-day moving averages. The 1.84% rise in the last 24 hours indicates that the market has received the news positively. An upward movement can be expected in the short term, but since the stock has not entered overbought territory, there is a risk that the rally may be limited.

RSI 14

58.5

MACD

4.22

24h Δ

1.84%

Canlı Grafikler